-
Validation of the Transcriptional Repressor Bach1 as a Novel Target to Enhance Antioxidant Response Pathway and Block Neurodegeneration in Parkinson’s Disease
… a transcriptional repressor, which is a protein that binds to a specific DNA site and prevents transcription of nearby … genes in the ventral midbrain. These studies will establish how altering Bach1 expression could be beneficial against … for new neuroprotective strategies in PD. Anticipated Outcome: This study will provide important …
-
Fox Trial Finder Ambassador Brings Attention to Urgent Need for Trial Volunteers
March 4, 2014
… Eli. Gary Rafaloff is a Fox Trial Finder Ambassador who is committed to spreading the word about the critical … in PD clinical trials. In a recent opinion piece for the Courier-Post, Gary, a seasoned trial participant himself, wrote about the urgent need for volunteers to fill PD trials to speed research …
-
Michael J. Fox Foundation to Fund Progressive Predictive Models of Parkinson’s Disease
November 14, 2005
… Michael J. Fox Foundation for Parkinson’s Research (MJFF) today announced the launch of a new $2 million initiative to … disease. Such models are crucial research tools for testing neuroprotective and neuroregenerative therapeutic … the course of the project will be dependent upon successful completion of these milestones. Letters of intent are due by …
-
Cinespia Takes Fans Back to the Future and Raises $80,000 for Team Fox
October 9, 2015
… In preparation for Marty McFly’s highly anticipated Back to the Future ( BTTF ) arrival on October 21, 2015, Team Fox … research. On September 27, Los Angeles-based film company Cinespia paired up with ZTE USA and the Team Fox …
-
The Michael J. Fox Foundation Awards $3 Million to Advance Parkinson's Disease Research
April 23, 2010
… NY — The Michael J. Fox Foundation for Parkinson’s Research today announced more than $3 million in previously … ending the first quarter of 2010. The funded projects complement the Foundation’s annually occurring Pipeline … in order to determine whether this process can be targeted therapeutically. Another project, led by Jochen …
-
FDA Issues ‘Letter of Support’ Encouraging Use of Synuclein-based Biomarker, αSyn-SAA, in Clinical Trials for Parkinson’s and Related Diseases
September 9, 2024
… (FDA) encouraged scientists and drug developers to use the alpha-synuclein seed amplification assay … research, which is shared with the broader research community in real time for ongoing discovery and validation … Heralded as “the study that’s changing everything” about how Parkinson’s is diagnosed, managed and treated, PPMI and …